AstraZeneca has an agreement in place to acquire Belgium-based EsoBiotec, a biotechnology company specializing in in-vivo cell therapies. The acquisition was announced by AstraZeneca on March 17, 2025. EsoBiotec’s operations will continue in Belgium, with the company becoming a wholly owned subsidiary of AstraZeneca. According to an AstraZeneca press release, the acquisition involves an initial payment of $425 million by AstraZeneca upon the closing of the deal. Source: Biopharm International 21/3/2025